Bolt Biotherapeutics Inc
NASDAQ:BOLT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
10.266
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bolt Biotherapeutics Inc
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company is headquartered in Redwood City, California and currently employs 91 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. BDC-2034 is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). CEA is a well-known tumor antigen expressed in various solid tumors with significant unmet medical need. BDC-3042 is an agonist antibody targeting Dectin-2, which is an innate immune receptor found on the surface of macrophages. PD-L1 Boltbody ISAC focused on the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company is headquartered in Redwood City, California and currently employs 91 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. BDC-2034 is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). CEA is a well-known tumor antigen expressed in various solid tumors with significant unmet medical need. BDC-3042 is an agonist antibody targeting Dectin-2, which is an innate immune receptor found on the surface of macrophages. PD-L1 Boltbody ISAC focused on the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.
